A Phase I Study of AZD5991 in Patients with Recurrent or Persistent Multiple Myeloma

Share
Print

Full Title

A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 Monotherapy and in Combination with Venetoclax in Subjects with Relapsed or Refractory Haematologic Malignancies

Purpose

The purpose of this study is to find the highest dose of the investigational drug AZD5991 that can be given safely in patients with multiple myeloma that has continued to grow or came back after chemotherapy.

Normally, cells in the body grow and die under a balanced control. Cancer develops when cells continue to grow and do not die as planned. AZD5991 binds to and inhibits a protein called MCL-1, preventing its ability to stop cells from dying.

AZD5991 is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that continued to grow or came back despite at least two prior regimens of treatment.
  • At least 2 weeks must pass since the completion of previous therapy and entry into the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients ages 18 to 85.

For more information about this study and to inquire about eligibility, please contact Dr. Anas Younes at 212-639-5059.

Protocol

18-117

Phase

I/II

Investigator

Co-Investigators